ArticleJournal of Korean medical science2026
Role of Renal Biomarkers in Sarcopenia or Frailty in Patients With Liver Cirrhosis.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSarcopenia and frailty are risk factors for poor prognosis in patients with liver cirrhosis. This study investigated the role of renal biomarkers in sarcopenia or frailty in patients with cirrhosis.
methodsA total of 78 patients with liver cirrhosis and serum creatinine levels < 1.5 mg/dL were analysed for serum renal biomarkers (creatinine-to-cystatin C ratio, interleukin [IL]-18, kidney injury molecule [KIM]-1, and neutrophil gelatinase-associated lipocalin [NGAL]), sarcopenia, and liver frailty index. Sarcopenia was assessed using the skeletal muscle index of the third vertebra. We analysed the risk of sarcopenia or frailty based on various renal biomarkers of cirrhosis.
resultsThe mean age was 59.2 years and 67.9% were men. The Child-Pugh class B score was noted in 17.9%. Sarcopenia or frailty (pre-frail and frail) was observed in 43 patients (55.1%). No significant differences in serum IL-18 (
conclusionA lower serum creatinine-to-cystatin C ratio was associated with an increased risk of sarcopenia or frailty in patients with cirrhosis and favourable renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.